Free Trial
OTCMKTS:BIXT

Bioxytran Q2 2023 Earnings Report

Bioxytran logo
$0.09 -0.01 (-7.01%)
As of 07/11/2025 03:49 PM Eastern

Bioxytran EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioxytran Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bioxytran Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Monday, July 31, 2023
Conference Call Time
10:00AM ET

Bioxytran Earnings Headlines

Bioxytran (OTCMKTS:BIXT) Trading Up 1.2% - Time to Buy?
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
See More Bioxytran Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioxytran? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioxytran and other key companies, straight to your email.

About Bioxytran

Bioxytran (OTCMKTS:BIXT) is a biotechnology and nutraceutical company focused on the development and commercialization of proprietary compounds for metabolic disorders and related conditions. Founded in 2011 and headquartered in Jupiter, Florida, the company combines pharmaceutical research with nutraceutical formulation to create novel oral therapies. Bioxytran’s mission is to address key areas of unmet medical need, particularly obesity, type 2 diabetes and nonalcoholic fatty liver disease (NAFLD), by leveraging its patented L-TUG drug delivery technology.

The company’s lead clinical candidate, BXT-100, is an oral formulation designed to regulate fat absorption and improve glucose metabolism through a novel mechanism of action that targets key enzymes in lipid processing. Preclinical studies have demonstrated BXT-100’s potential to reduce weight gain and lower blood glucose in animal models, supporting plans for first-in-human trials. In parallel, Bioxytran markets a line of dietary supplements under its trade name, offering consumers products aimed at supporting healthy weight management and metabolic wellness. These products are distributed through e-commerce platforms and select retail partners in the United States, Canada and Europe.

Bioxytran’s research and development efforts are supported by collaborations with academic institutions and contract research organizations, while manufacturing is conducted under cGMP conditions at third-party facilities. The company holds multiple patents covering its L-TUG delivery system and associated compositions. Bioxytran has also forged strategic partnerships to advance regulatory submissions and expand its global footprint, with ongoing initiatives targeting markets in Asia and Latin America.

The management team is led by Chief Executive Officer Stephen L. Yiu, who brings over two decades of experience in pharmaceutical R&D and product commercialization. Chief Scientific Officer Dr. Richard S. Henderson oversees Bioxytran’s discovery programs, while Chief Financial Officer Robert C. Shapiro manages corporate finance and investor relations. Together, the leadership team is steering the company toward clinical milestones and potential commercialization of its first therapeutic candidates.

View Bioxytran Profile

More Earnings Resources from MarketBeat